A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two-Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants with Parkinson’s Disease (PD)

Grant

Date/time Interval

  • January 3, 2018 - January 2, 2022
  • Total Award Amount

  • 241251.00
  • Direct Costs

  • 193001.00
  • Sponsor Award Id

  • Contributor

  • Amara, Amy   Investigator  
  • Stover, Natividad   Principal Investigator